Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PERPRISE: A Prospective Non-interventional Study Evaluating the Effectiveness of Perampanel (Fycompa®) as Only Add-on Treatment in Patients With Primary or Secondarily Generalized Tonic-clonic Seizures

NCT04202159 is registered in ClinicalTrials.gov with Eisai GmbH as lead sponsor.

NCT NCT04202159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04202159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PERPRISE: A Prospective Non-interventional Study Evaluating the Effectiveness of Perampanel (Fycompa®) as Only Add-on Treatment in Patients With Primary or Secondarily Generalized Tonic-clonic Seizures
Lead sponsor
Eisai GmbH
Phase
Observational
Overall status
Completed
Start date
January 21, 2020
Completion date
March 31, 2023
Enrollment
187 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

seizures